Vanda Pharmaceuticals Inc VNDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VNDA is a good fit for your portfolio.
News
-
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
-
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
-
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
-
Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet
-
Vanda Pharmaceuticals shares jump 30% after FDA approval of Fanapt for bipolar I disorder
-
Vanda Pharmaceuticals Shares Jump 17% After FDA Approved Fanapt for Bipolar I Disorder
-
Vanda Pharmaceuticals' Fanapt Gets FDA Approval for Bipolar I Disorder
-
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Trading Information
- Previous Close Price
- $4.56
- Day Range
- $4.43–4.57
- 52-Week Range
- $3.30–7.00
- Bid/Ask
- $4.50 / $4.62
- Market Cap
- $257.77 Mil
- Volume/Avg
- 923,301 / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 62.05
- Price/Sales
- 1.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 203
- Website
- https://www.vandapharma.com
Comparables
Valuation
|
Metric
|
VNDA
|
CBAY
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | 62.05 | — | — |
Price/Book Value | 0.48 | 12.65 | 3.52 |
Price/Sales | 1.36 | 111.01 | — |
Price/Cash Flow | 19.37 | — | — |
Price/Earnings
VNDA
CBAY
EWTX
Financial Strength
|
Metric
|
VNDA
|
CBAY
|
EWTX
|
|---|---|---|---|
Quick Ratio | 4.82 | 10.70 | 18.98 |
Current Ratio | 4.94 | 10.96 | 19.50 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
VNDA
CBAY
EWTX
Profitability
|
Metric
|
VNDA
|
CBAY
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | 2.20% | −30.06% | −24.36% |
Return on Equity (Normalized) | 2.62% | −51.97% | −25.87% |
Return on Invested Capital (Normalized) | 2.57% | −30.87% | −29.82% |
Return on Assets
VNDA
CBAY
EWTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cffmsxjxbc | Lnmwd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lygthbc | Pyjsqb | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Msgtssjj | Vjpfr | $97.8 Bil | |
MRNA
| Moderna Inc | Svxcwvvpp | Nhww | $38.8 Bil | |
ARGX
| argenx SE ADR | Lnncksdh | Vgk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mcvjzprn | Vnxwm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Spkpfpcnx | Htzcm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pmzmcdtp | Psxxxr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ppssncbr | Jmfpbs | $12.5 Bil | |
INCY
| Incyte Corp | Mttqgqkdt | Sjjrbtl | $11.5 Bil |